1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
Global Acute Lymphoblastic Leukemia Clinical Trials Research Trends and Insights Report- Analysis of Trial Phases, Status, Markets, Recruitment, Types, Enrolment, Intervention and Companies

Global Acute Lymphoblastic Leukemia Clinical Trials Research Trends and Insights Report- Analysis of Trial Phases, Status, Markets, Recruitment, Types, Enrolment, Intervention and Companies

  • September 2017
  • 520 pages
  • ID: 5139457
  • Format: PDF
  • VPAResearch

Summary

Table of Contents

Search Inside

Acute lymphoblastic leukemia (ALL) clinical trials report from VPA Research provides comprehensive analysis and trends in global Acute lymphoblastic leukemia (ALL) disease clinical trials. The research work analyzes the evolution of Acute lymphoblastic leukemia (ALL) clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Acute lymphoblastic leukemia (ALL) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Acute lymphoblastic leukemia (ALL) clinical trials.

Scope of the Report-
- Number of Acute lymphoblastic leukemia (ALL) clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Acute lymphoblastic leukemia (ALL)
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Acute lymphoblastic leukemia (ALL) clinical trials worldwide are listed

Reasons to Buy
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market

Executive Summary

Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer among children and second most common acute Leukemia in adults. The condition is also known as acute lymphocytic Leukemia or acute lymphoid Leukemia. It is an acute form of Leukemia, rapidly progressing towards mortality in few months. ALL originates typically in lymphocytes (white blood cells) and expands into bone marrow and blood. Occasionally, it expands into liver, spleen and also to central nervous system.

Some of the recent developments in ALL include-
- US FDA approved first chimeric antigen receptor T cell (CAR-T) therapy for B-cell ALL in August 2017.
- ULCA’s Combination of triapine (3-AP) and DI-82 (to lower nucleotide level) and VE-822 (to inhibit ATR enzyme) found to activate “DNA replication stress response” in mice.
- Pfizers’ antidrug conjugate- Besponsa (inotuzumab ozogamicin) gains US FDA approval
- Researchers studying type II topoisomerase enzyme, found it to snip the DNA double strand, allowing transcription and replication to occur, including Leukemia.
- Children’s Hospital of Philadelphia researchers uncover protein network signals found to drive myeloid Leukemias.
- Australian National University working on using novel agents such as CX-5461 with advanced mechanisms of action in chemotherapy to treat Leukemia.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2017

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on